Scott Loughhead

Joined SQZ Biotech in 2015 and has been instrumental in the translational research for both SQZ® APC and SQZ® eAPC programs from preclinical proof-of-concept to successful IND submission and approval. Dr. Loughhead has worked closely with Roche since the inception of the collaboration. Over 15 years of immunology experience. Holds a Ph.D. in Immunology from Harvard University where he focused on immune surveillance by CD8 T cells.